Precision Oncology and biotechnology company FogPharma and radiopharmaceutical biotechnology company ARTBIO have announced a partnership to develop cancer therapies. The financial terms of the agreement have not been disclosed; however, both parties have agreed to contribute equally across all stages from research to commercialization.

The collaboration will leverage FogPharma’s Helicon platform's peptide capabilities and ARTBIO’s AlphaDirect platform for radioligand therapies to jointly develop Helicon-enabled ARTs (HEARTs) for multiple cancers. 

Massachusetts-based FogPharma is discovering and developing Helicon Therapeutics, a new class of precision medicines that can reach difficult targets. These peptides can enter cells and regulate interactions between proteins and DNA. By leveraging Helicon Therapeutics' potential, the company seeks to target intracellular mechanisms known to play pivotal roles in diseases.